MRNA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
145.0M
-62.7%
389.0M
-42.6%
678.0M
-33.3%
1.0B
+615.5%
142.0M
Cost of Revenue
93.0M
-90.3%
955.0M
+111.3%
452.0M
+118.4%
207.0M
+73.9%
119.0M
Gross Profit
52.0M
+109.2%
-566000000
-350.4%
226.0M
-72.1%
809.0M
+3417.4%
23.0M
Operating Expenses
867.0M
+5.5%
822.0M
-24.1%
1.1B
+1.3%
1.1B
+14.9%
930.0M
R&D
651.0M
+0.3%
649.0M
-16.3%
775.0M
-3.2%
801.0M
+14.4%
700.0M
SG&A
216.0M
+24.9%
173.0M
-43.8%
308.0M
+14.9%
268.0M
+16.5%
230.0M
Operating Income
-815000000
+41.3%
-1388000000
-62.0%
-857000000
-229.6%
-260000000
+71.3%
-907000000
EBITDA
-752000000
+43.4%
-1329000000
-68.2%
-790000000
-279.8%
-208000000
+75.5%
-850000000
Net Income
-782000000
+41.8%
-1343000000
-62.6%
-826000000
-313.0%
-200000000
+75.8%
-825000000
EPS (Basic)
$-1.97
+42.1%
$-3.40
-61.1%
$-2.11
-313.7%
$-0.51
+76.1%
$-2.13
EPS (Diluted)
$-1.97
+42.1%
$-3.40
-61.1%
$-2.11
-313.7%
$-0.51
+76.1%
$-2.13
Shares (Diluted)
398.0M
+0.8%
395.0M
+0.8%
392.0M
+0.5%
390.0M
+0.5%
388.0M
Moderna (MRNA) โ€” Financials